Nucleic Acid, Nucleoside, or Nucleotide
Moderna and Merck Report Sustained 49% Risk Reduction in Recurrence or Death with mRNA-Keytruda Combo at Five Years in Melanoma Trial
Moderna; Merck; Keytruda; intisemeran autogene; mRNA-4157; melanoma; recurrence-free survival; Phase 2b
CRISPR Pioneers Jennifer Doudna and Fyodor Urnov Launch Aurora Therapeutics for Custom CRISPR Therapies
Aurora Therapeutics; CRISPR; gene editing; personalized therapies; Jennifer Doudna; Fyodor Urnov; rare diseases; Menlo Ventures
BioNTech and UPenn Launch $50M Seed Fund for Early-Stage Biotechs
BioNTech; UPenn; seed fund; $50M; mRNA; biotech startups
Orum Therapeutics Appoints Chad May as Chief Scientific Officer
Orum Therapeutics; Chad May; CSO; Degrader-Antibody Conjugates; DAC; Targeted Protein Degradation
Moderna Lands CEPI as New Backer for Its Pandemic Flu (H5 Bird Flu) Program
Moderna; CEPI; Coalition for Epidemic Preparedness Innovations; pandemic influenza; H5 bird flu; mRNA vaccine; Phase 3 trial; pandemic preparedness; vaccine development; funding
GSK strikes RNA-based neuro and kidney disease collaboration with CAMP4 Therapeutics
GSK; CAMP4 Therapeutics; RNA therapeutics; regulatory RNA; antisense oligonucleotides; ASO; RAP Platform; neurodegenerative diseases; kidney disease; renal disease; gene upregulation; biotech collaboration; licensing deal; milestone payments; tiered royalties
FDA Commissioner Makary Addresses COVID-19 Vaccine Safety Concerns Amid Internal Debates and Investigations
Marty Makary; FDA; COVID-19 vaccine; myocarditis; vaccine deaths; safety warnings; RFK Jr.; mRNA vaccines
J&J-backed Cellular Origins raises $40M for cell therapy manufacturing
Cellular Origins; Johnson & Johnson; Series A; $40 million; cell therapy manufacturing; Constellation platform; robotic automation; ATMP; TTP Group; scalable manufacturing
SanegeneBio raises over $110M Series B after Lilly RNAi deal
SanegeneBio; Series B financing; $110 million; Eli Lilly; RNA interference; RNAi therapeutics; metabolic diseases; Lilly collaboration; clinical-stage assets; liver-targeted RNAi; extrahepatic RNAi; biotech fundraising 2025
Novartis antibody ianalumab helps prolong control of rare blood disorder ITP
Novartis; ianalumab; primary immune thrombocytopenia; ITP; rare blood disorder; antibody; VAYHIT2 trial; time to treatment failure; disease control; ASH 2025; Promacta; eltrombopag